| Mr Michael Jon Mattice, MD | |
|
3725 10th Court, Vero Beach, FL 32960 | |
| (772) 213-3621 | |
| (772) 213-3631 |
| Full Name | Mr Michael Jon Mattice |
|---|---|
| Gender | Male |
| Speciality | Preventive Medicine - Medical Toxicology |
| Location | 3725 10th Court, Vero Beach, Florida |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821075219 | NPI | - | NPPES |
| ME0049088 | Other | FL | MEDICAL LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083T0002X | Preventive Medicine - Medical Toxicology | ME0049088 (Florida) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mr Michael Jon Mattice, MD 3725 10th Court, Vero Beach, FL 32960 Ph: (772) 213-3621 | Mr Michael Jon Mattice, MD 3725 10th Court, Vero Beach, FL 32960 Ph: (772) 213-3621 |
News Archive
Emergency medical technicians (EMTs), military medics, and emergency room physicians could one day be better able to treat victims of vehicular accidents, gunshot wounds, and battlefield injuries thanks to a new device under development that may more accurately assess the effects of blood loss due to hemorrhage.
ChemoCentryx, Inc., today announced that it reported positive Phase I results for its novel drug candidate CCX354 at the Annual European Congress of Rheumatology (EULAR). CCX354 is the Company's orally-active small molecule drug candidate designed to specifically target the CCR1 chemokine receptor for the treatment of patients with rheumatoid arthritis (RA).
The study, which looked at 120 people over the age of 60, found people who complained of significant memory problems but still had normal performance on memory tests had reduced gray matter density in their brains even though they weren't diagnosed with Alzheimer's disease or mild cognitive impairment (MCI).
Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, announced that its most advanced ImmTAC drug, IMCgp100 for the treatment of late stage melanoma, has reached Maximum Tolerated Dose (MTD) and the dose escalation part of this Phase I clinical study has been completed. The company has now initiated a Phase IIa clinical trial in the UK and USA.
The "What the Health?" panelists are taking a break for two weeks. But since the Supreme Court recently scheduled arguments in the case challenging the constitutionality of the Affordable Care Act, it seemed like a good opportunity to replay an episode from March, when the law turned 10.
› Verified 1 days ago
Richard Orlo Haight, MD Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 1900 27th St, Vero Beach, FL 32960 Phone: 772-794-7400 Fax: 772-794-7453 | |
Dr. Peter Roman Holyk, M.D.. C.N.S. Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 1345 36th St, Suite B, Vero Beach, FL 32960 Phone: 772-567-1500 Fax: 772-567-1505 |